23 research outputs found
The preclinical and clinical pharmacology of novel histone deacetylase inhibitors
No full textEThOS - Electronic Theses Online ServiceGBUnited Kingdo
A phase 1 first-in-human (FIH) dose-escalation (DE) study of the oral dual PI3K/mTOR inhibitor PQR309 in patients (pts) with advanced solid tumors: Final DE results.
No full textWhat factors influence advanced ovarian cancer patient (AOC pt) outcomes to phase I trial treatments?
No full textClinical outcomes in advanced cervical cancer (CC) and endometrial cancer (EC) patients (pts) treated in phase I trials of novel molecularly targeted agents (MTAs).
No full textFeasibility of circulating tumour cell (CTC) enumeration and molecular profiling (MP) as a biomarker in advanced endometrial cancer (aEC).
No full textCORAIL trial: Randomized phase III study of lurbinectedin (PM01183) versus pegylated liposomal doxorubicin (PLD) or topotecan (T) in patients with platinum-resistant ovarian cancer.
No full textPhase 1 multicenter, open-label study to establish the maximum tolerated dose (MTD) of two administration schedules of E7389 (eribulin) liposomal formulation in patients (pts) with solid tumors.
No full textA first-in-human phase I/II trial of SRA737 (a Chk1 Inhibitor) in subjects with advanced cancer.
No full text
A phase I/II first-in-human trial of oral SRA737 (a Chk1 inhibitor) given in combination with low-dose gemcitabine in subjects with advanced cancer.
No full text
